Cardiac health in patients with hepatitis B virus-related cirrhosis

Wei Yuan, MMa, Hong-Zhou Lu, MD*b, Xue Mei, MMa, Yu-Yi Zhang, MMa, Zheng-Guo Zhang, MMa, Ying Zou, MMa, Jie-Fei Wang, BMb, Zhi-Ping Qian, MMa,∗, Hong-Ying Guo, MMa,∗

Abstract
Not only alcoholic cirrhosis related to cardiac dysfunction, cirrhosis caused by nonalcoholic etiology including hepatitis B virus (HBV) infection also related to impaired cardiac health. The aims of present study were to perform a noninvasive evaluation of cardiac function and to evaluate exercise performance in HBV related cirrhotic patients without typical symptoms of cardiac disease.

Seventy-nine HBV related cirrhotic patients and 103 matched subjects without a previous history of cardiac involvement were recruited. Clinical examination and cardiac health evaluation were performed. The incidence, risk factors of cardiac dysfunction and exercise tolerance were investigated.

A correlation between QTc interval and model for end-stage liver disease score (R = 0.239, P = .018) was detected, however, the connection between QTc prolongation and the severity of liver disease was uncertain. Patients with HBV related cirrhosis had a tendency toward left ventricular wall thickening (P = .007). Forty-one patients (51.90%) were in accordance with the definition of cirrhotic cardiomyopathy, and a significant increase in the incidence of cardiac diastolic dysfunction (CDD) could be found with increasing Child-Pugh grade (P = .004). HBV related cirrhotic patients with CDD had a higher level of pro-brain natriuretic peptide (P = .025), international normalized ratio (P = .010) Child-Pugh score (P = .020), and a higher proportion of ascites (P < .001). The higher Child-Pugh score (odds ratio = 1.662, P = .010) was an independent diagnostic predictor of CDD. The cardiac depression and exercise tolerance also got worse with increasing Child-Pugh score (P < .001).

Impaired cardiac health was common in HBV related cirrhotic patients. Cardiogenic factors must be carefully considered in the integral therapy of cirrhosis. Hepatology physicians should lay emphasis on exercise training in daily life.

Abbreviations: ALT = alanine aminotransferase, AST = aspartate transaminase, BNP = brain natriuretic peptide, CDD = cardiac diastolic dysfunction, CHB = chronic hepatitis B, CK = creatine kinase, EF = ejection faction, HBV = hepatitis B virus, INR = international normalized ratio, IVST = interventricular septum thickness, LVEDD = left ventricular end-diastolic diameter, LVESD = left ventricular end-systolic diameter, LVPWT = left ventricular posterior wall thickness, MELD = model for end-stage liver disease.

Keywords: cardiac health, cirrhotic cardiomyopathy, hepatitis B virus, liver cirrhosis

1. Introduction
Hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis in the Asian-Pacific region. Patients with either compensated or decompensated liver cirrhosis may face several complications including impaired cardiac health. It was ever believed that cardiac dysfunction was more common in patients with alcoholic cirrhosis. However, recent studies arrived at the conclusion that potential cardiac complications are also connected to nonalcoholic cirrhosis. Patients with liver cirrhosis are under the condition of hemodynamic disorder, including decreased systemic vascular resistance, volume redistribution, and impaired cardiac function. Meanwhile, impaired cardiac function may also induce further liver injury.

The cross-talk between cardiac and hepatic dysfunction can lead to high mortality, as the data showed that impaired heart function resulted in up to 25.8% of cirrhotic patients’ deaths. According to the diagnostic criteria by the Working Party for Cirrhotic Cardiomyopathy (CCM), chronic heart dysfunction can be defined as abnormal systolic responses to stress and/or diastolic dysfunction at rest without primary cardiac disease. However, cirrhotic patients with cardiac dysfunction always present a serious of untypical symptoms. At the same time, the medical treatment like nonselective beta-blockers, which could impact systemic hemodynamics, was often prescribed for cirrhotic patients with portal hypertension. Based on this fact, cardiac health should be paid attention in the integral treatment of liver cirrhosis. Currently, little is known about the exact incidence and risk factors of cardiac dysfunction in the cirrhotic populations. Therefore, the primary aim of this study is to evaluate the cardiac function, by serum markers, electrocardiogram (ECG) and ultrasound cardiogram (UCG), in the patients...
with HBV related cirrhosis, which is most common in Asian-Pacific region. Additionally, we further assessed the exercise tolerance and cardiac depression in patients with HBV related cirrhosis, as few studies on physical activity, which is associated with quality of life and reduced cardiac mortality,[8] were ever reported in cirrhotic patients.

2. Methods

2.1. Patients and study design

From January 1, 2017 to October 31, 2017, the data from 158 HBV related cirrhotic patients with atypical cardiac manifestations were reviewed. Atypical cardiac manifestations referred to the absence of typical symptoms (breathlessness, orthopnoea, paroxysmal nocturnal dyspnea) and specific signs (elevated jugular venous pressure, third heart sound, and laterally displaced apical impulse).[9] Diagnosis of liver cirrhosis was based on clinical observations, laboratory parameters, and imageology examination. The fibrosis scores of aspartate aminotransferase-to-platelet ratio index and Fibrosis 4 Score, tissue stiffness or liver biopsy if necessary was used to evaluate the morphology of liver.[10] For the present analysis, 79 patients were enrolled as controls. CHB was defined as HBsAg seropositive and anemia), and 13 patients with incomplete data on cardiac function, such as peak velocities of early diastolic filling (E wave)/late diastolic filling (A wave), E/A ratio, early diastolic annular velocity (E’ wave), E/E’ ratio, deceleration time (DT), ejection fraction (EF), and pulmonary artery systolic pressure, were evaluated by M-mode echocardiography and tissue doppler imaging.

Cardiac systolic dysfunction in cirrhotic patients connects to EF <55% and reginal wall motion abnormality.[11,12] The definition of cardiac diastolic dysfunction (CDD) is as follows[13]:

1. Impaired relaxation refers to E/A ratios ≥1.5, E/E’ ratios >10, and DT >150 ms;
2. Pseudonormalization refers to E/A ratios >1.0, E/E’ ratios >10, and DT >150 ms;
3. Severe diastolic dysfunction refers to E/A ratios >1.5, E/E’ ratios >10, and DT <150 ms.

2.4. Cardiac depression and exercise tolerance

The Chinese version of Cardiac Depression Scale (C-CDS) was used to evaluate the exercise confidence.[14] It is a self-report questionnaire consisted of 25 items to assess the domains of sleep, anhedonia, uncertainty, mood, cognition, hopelessness, and inactivity.[14]

Exercise tolerance was assessed by the 6-minute walk test (SMWT). SMWT was not performed on cirrhotic patients with Child-Pugh grade C due to the high incidence of complications, such as refractory ascites, mild-to-moderate encephalopathy, and coagulopathy. The SMWT was carried out according to American Thoracic Society guidelines.[15] Briefly, patients were asked to walk at their usual pace along a straight 50-meter flat way. The distance was recorded at the end of the 6 minutes. The patients were encouraged to walk as much as possible, but also allowed to quit if there were intolerance symptoms.

2.5. Statistical analysis

Statistical analysis was performed with SPSS 16.0 software. Continuous variables with normal distributions are reported as medians (quartiles) and analyzed by t-test or 1-way ANOVA analysis of variance. Continuous variables with non-normal distributions are reported as medians (quartiles) and analyzed by Mann–Whitney U test or Kruskal–Wallis test. Categorical variables are expressed as frequencies, analyzed by chi-square test or Fisher exact test. Correlation between variables was determined by the Spearman rho test. Binary logistic regression was used for modeling the relationships between CDD and clinical parameters.

3. Results

3.1. General characteristics

Baseline characteristics including demographics and clinical parameters were recorded as shown in Table 1. All selected patients of HBV related cirrhosis were prescribed with nucleos(t)ide analogs according to the clinical practice. Seventy-nine cirrhotic
patients were enrolled in the cohort of this study. Meanwhile, 103 matched CHB patients were enrolled as controls. To avoid the bias between the 2 groups, the age, gender, status of e antigen, and viral loads were analyzed, there were no significant differences of age (53[41–62] vs 59[41–67] years, \(P=\cdot763\)), gender (male/female [50/29] vs [57/46], \(P=\cdot280\)), e antigen status (positive/negative [34/45] vs [51/52], \(P=\cdot454\)) between HBV related cirrhotic patients and the control group. Viral loads of all patients in both groups were lower than 100 IU/ml.

### 3.2. ECG manifestations

There was no significant difference of rest HR between HBV related cirrhotic patients and the control group (75 [68–92] vs 74 [62–84] beats per minute, \(P=\cdot076\)). However, HBV related cirrhotic patients had a longer QTc interval duration than the control group (437 [414–457] vs 420 [403–435] ms, \(p<\cdot001\)). There was a weak correlation between QTc interval and MELD score (\(R=0.239, P=\cdot018\), Fig. 1). However, the proportions of QTc prolongation in controls, Child-Pugh grade A, grade B, and

### Table 1

Baseline characteristics of patients in controls and HBV related cirrhosis group.

| Characteristics | Controls (\(N=103\)) | HBV-cirrhosis (\(N=79\)) | \(P\)-value |
|-----------------|------------------------|---------------------------|-------------|
| Age, yr         | 59 (41–67)             | 53 (41–62)                | .763        |
| Gender (Male/female) | 57/46                | 50/29                     | .280        |
| Platelet count (10^9/L) | 133 (99–188)         | 80 (57–175)               | <.001       |
| ALT, U/L        | 55 (19–363)            | 43 (21–125)               | .193        |
| AST, U/L        | 50 (31–339)            | 75 (39–191)               | .119        |
| dCI, μmol/L     | 62.0 (52.9–70.4)       | 64.3 (49.8–79.9)          | .826        |
| TBIL, μmol/L    | 26.7 (13.4–192.3)      | 69.2 (32.6–235.9)         | <.001       |
| TC, mmol/L      | 3.74 (2.91–4.10)       | 2.87 (1.83–3.36)          | <.001       |
| TG, mmol/L      | 1.31 (0.81–2.15)       | 0.92 (0.60–1.20)          | <.001       |
| CK, U/L         | 62 (41–82)             | 78 (46–99)                | .444        |
| Pro-BNP, pg/ml  | 262.69 (168.87–496.01) | 1129.02 (339.81–1861.90) | .001        |
| INR             | 1.10 (1.02–1.39)       | 1.48 (1.34–2.01)          | <.001       |
| HBeAg (Positive/negative) | 51/52           | 34/45                      | .454        |
| MELD score      | NA                     | 11.65 (8.53–17.87)        | NA          |
| Child-Pugh score| NA                     | 8 (7–9)                    | NA          |

ALT = alanine aminotransferase, AST = aspartate transaminase, BNP = brain natriuretic peptide, CHB = chronic hepatitis B, CK = creatine kinase, HBV = hepatitis B virus, INR = international normalized ratio, MELD = model for end-stage liver disease, NA = not applicable, sCI = serum creatinine, TBIL = total bilirubin, TC = total cholesterol, TG = triglyceride.

Figure 1. Electrocardiogram manifestation in patients with cirrhosis and no-cirrhosis groups. (A) Heart rate (\(P=\cdot076\)), (B) QTc interval (\(P<\cdot001\)), (C) Correlations between QTc interval and MELD score (\(r=0.239, P=\cdot018\)). MELD = model for end-stage liver disease.
grade C groups were 8.73%, 13.66%, 32.0%, and 31.25%, respectively (P = .069).

3.3. UCG manifestations

The UCG manifestations of the patients with both HBV-related cirrhosis and noncirrhosis, were summarized in Table 2. No statistical significances of LVEDD, IVST, and LVPWT were observed between the 2 groups. Compared with controls, however, LVESD was thicker in patients with cirrhosis (Table 2).

Forty-one patients (51.90%) of HBV-related cirrhotic patients were in accordance with the definition of CCM. As to EF value, which is associated with cardiac systolic function, there was no significant difference among all groups. A total of 68 enrolled patients (37.57%) had some degree of CDD: 30 patients (31.25%) in the control group, 7 patients (28.00%) in Child-Pugh grade A, 20 patients (60.61%) in Child-Pugh grade B, and 11 patients (32.38%) in Child-Pugh grade C. Further analysis showed that patients with HBV-related cirrhosis (38, 48.10%) had a higher incidence of CDD than controls (30, 29.13%) (P < .001). However, there were no differences between the groups in serum ALT, serum creatinine, total bilirubin, total cholesterol, troponin I, and MELD score levels (Table 1). To control the confounding effects between the variables, binary logistic regression modeling was performed. The platelet count, pro-BNP, INR, Child-Pugh score, and the proportion of ascites were analyzed. The results showed the high incidence of CDD in total (N, %) 30, 29.13 38, 48.10 .008

### Table 3

| Items                  | No-CDD (N = 114) | CDD (N = 68) | P-value |
|------------------------|------------------|--------------|---------|
| Platelet count, 10^9/L | 123 (82–192)     | 116 (72–139) | .046    |
| ALT, U/L               | 94 (34–626)      | 37 (22–92)   | .213    |
| Tc, μmol/L             | 59.6 (49.6–73.1) | 62.0 (50.4–75.9) | .606    |
| TBI, μmol/L            | 113.9 (21.0–202.0) | 51.2 (13.1–169.8) | .343    |
| TC, mmol/L             | 3.05 (2.48–3.98) | 3.29 (2.69–3.63) | .128    |
| CK, U/L                | 63 (45–98)       | 52 (39–98)   | .296    |
| Pro-BNP, pg/ml         | 298.83 (180.55–460.75) | 978.28 (357.36–1882.00) | .025    |
| TNL, ng/ml             | 0.025 (0.003–0.036) | 0.012 (0.001–0.0339) | .387    |
| INR                    | 1.29 (1.06–2.01) | 1.41 (1.22–1.61) | .010    |
| Child-Pugh score       | 7 (6–9)          | 8 (6–10)     | .020    |
| MELD score             | 6.55 (3.55–12.89) | 10.39 (4.44–16.21) | .139    |
| Ascites (N, %)         | 14 (12.28)       | 33 (48.53)   | <.001   |

**ALT** = alanine aminotransferase, **AST** = aspartate transaminase, **BNP** = brain natriuretic peptide, **CDD** = cardiac diastolic dysfunction, **CK** = creatine kinase, **INR** = international normalized ratio, **MELD** = model for end-stage liver disease, **SG** = serum creatinine, **TBI** = total bilirubin, **TC** = total cholesterol, **TG** = triglycerides, **TNL** = troponin I.
including cardiac depression and exercise tolerance, ECG and UCG manifestations were focused.

A significant longer QTc interval duration could be detected in cirrhotic patients when compared with the control group, which was in line with previous researches.\textsuperscript{18–20} A longer QTc interval duration could result from delayed repolarization of cardiac muscle, which was possibly associated with volume overload, sympathoadrenergic activity and portal hypertension in cirrhotic patients.\textsuperscript{18,20} On the other hand, Li et al also showed that the prolonged QTc interval duration became normal in 17 of 20 patients undergoing liver transplantation,\textsuperscript{19} indicating the impact of liver cirrhosis on heart function.\textsuperscript{21,22} Additionally, QTc interval was found weakly associated with MELD score. The proportion of QTc prolongation had an upward tendency with the increase of Child-Pugh grade. However, no significant difference was detected. With the inconsistency of above results, although electrophysiological changes were common in patients with HBV-related cirrhosis, we could hardly establish the connection between QTc prolongation and the severity of HBV related cirrhosis. QTc interval might be affected by some other decisive factors independent of cirrhosis, such as alcohol consumption, hepatic venous pressure gradient (HVPG) and plasma calcium level.\textsuperscript{23}

There are many ways to evaluate heart function, including UCG and cardiac magnetic resonance (CMR).\textsuperscript{9} CMR is known as the gold standard for the measurements of volumes and EF of the heart, but is limited by higher costs and lower availability.\textsuperscript{9} UCG, which is considered feasible and precision, was used to access the heart function in our study. Ventricular wall thickening occurred in patients with liver cirrhosis according to the data of our study. Patients with liver cirrhosis had a thicker LVSED than noncirrhotic patients. The exact pathogenesis between heart wall thickness and liver cirrhosis is still uncertain. The possible explanation could be as follows:

1. volume redistribution and cardiac overload might lead to cardiac hypertrophy\textsuperscript{21};
2. hyperactivity of renin-angiotensin-aldosterone system could result in an increase in both the number and size of cardiac cells in the animal model.\textsuperscript{24}

In our study, we found a similar incidence of systolic function between the cirrhotic and non-cirrhotic group, and the EF value showed no significant difference between different groups. Meanwhile, 30 patients (29.13\%) in the noncirrhotic group and 38 patients (48.10\%) in the cirrhotic group had evidence of CDD. The proportion of CDD increased significantly with the severity of liver disease. Most of the enrolled subjects, both cirrhotic group (30 subjects, 81.08\%) and the control group (22 subjects, 73.33\%), had impaired cardiac relaxation (mild CDD). Child-Pugh grade B group had highest incidence of CDD. Similar results were ever reported, and the mechanism of CDD in liver cirrhosis was possibly associated with hyperdynamic circulation.\textsuperscript{23} In total, 51.90\% of HBV-related cirrhotic patients without significant manifestations were diagnosed as CCM. Due to the heavy use of non-selective beta-blocker and diuretics, which could affect the system hemodynamics, cardiac condition should be taken into account in the treatment of cirrhosis.

Only a few studies have focused on the risk factors of CDD in liver disease. Compared with no-CDD group, patients with CDD showed higher levels of INR, pro-BNP and Child-Pugh score and lower level of platelet count. The increase of INR and decrease of platelet count resulted in an advanced liver condition. Pro-BNP is a reliable biomarker to evaluate cardiac dysfunction in early...
stage.[26] In our study, patients with CDD had a higher level of pro-BNP. The elevation of pro-BNP might be linked with volume overload, and the persistent existence of CDD might further elevate the level of pro-BNP. Furthermore, the presence of ascites had a high incidence in CDD group, because cirrhotic patients with complication of ascites might be under a worse condition of volume overload and HVPG.[22] However, in the regression model, only Child-Pugh score was an independent predictor of CDD incidence. In other words, the severity of liver disease itself was closely related to cardiac dysfunction, as well as the hyperdynamic circulating state.

The SMWT is a low-cost and easy-to-conduct assessment for exercise tolerance. It is generally safe for patients with liver disease.[27] Previous study showed distance of SMWT was associated with nutritional status and mortality in patients with severe liver disease.[28,29] As the data shown in Figure 2, patients in Child-Pugh grade B had the least exercise confidence, while the distance of SMWT decreased with the severity of liver disease. Although the UCG has not shown impairment of cardiac function, the cirrhotic complications, including volume overload (ascites) and myodystrophia, resulted in poor exercise tolerance. In line with the previous findings, this observation suggested distance of SMWT was associated with the severity of liver disease. However, the reliability and validity of SMWT in liver disease are relatively weak. A study on SMWT in patients with liver transplantation suggested though the SMWT was a simple test of physical functioning, it was difficult to apply because of a low level of fitness in this population.[17] In our study, a proportion of cirrhotic patients with Child-Pugh Grade C were excluded due to the severity of illness, thus, sampling bias might not be avoided. The results of SMWT could only be considered as a helpful hint to indicate an advanced condition. According to the practical management of chronic heart failure, the physical exercise is the cornerstone to improve functional status and survival rate.[30,31] It might be necessary to stress the importance of exercise training in cirrhotic patients.

There are some limitations to the study. First, this was a single-center retrospective study and was limited by small sample size. Further work should include a follow-up work designed to evaluate whether cardiac function is connected with the severity of liver disease and concomitant medication, such as nonselective beta-blocker and diuretics. Quantitative analysis of liver cirrhosis, such as apparent diffusion coefficient value and cirrhosis risk score, should be enrolled in the future study.[32,33] Second, stress ECG or UCG was not further performed to evaluate the compensatory capacity of the heart. Third, patients with cirrhosis are often under the condition of portopulmonary hypertension, it needs further study on right cardiac function in cirrhotic patients. Finally, functional tests such as SMWT and C-CDS are not liver specific, a certain degree of bias might be occurred. The result of exercise tolerance and confidence might only work as a cue for clinical management.

5. Conclusion
Electrophysiological changes and cardiac dysfunction were common in patients with HBV related cirrhosis. Cardiac condition must be carefully considered in the integrated therapy of liver cirrhosis. Hepatology physicians should lay emphasis on exercise training in daily life to improve exercise confidence and exercise tolerance.

Author contributions
Conceptualization: Jie-Fei Wang.
Data curation: Xue Mei.

References
[1] Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 1953;32:1025–33.
[2] Yang YY, Lin HC. The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc 2012;75:619–23.
[3] Wronski J, Fieder P, Kwośkaz M, et al. Retrospective analysis of liver cirrhosis influence on heart walls thickness. Pathol Res Pract 2015;211:145–9.
[4] Ortiz-Olvera NX, Castellanos-Pallares G, Gomez-Jimenez LM, et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 2011;10:321–6.
[5] Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268–78.
[6] Moller S, Hove JD, Dixen U, et al. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013;167:1101–8.
[7] Kato T, Nizuma S, Inuzuka Y, et al. Analysis of liver metabolism in a rat model of heart failure. Int J Cardiol 2012;161:130–6.
[8] Ding R. Exercise-based rehabilitation for heart failure: clinical evidence. Adv Exp Med Biol 2017;1000:31–49.
[9] Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
[10] Fuku H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629–50.
[11] Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–61.
[12] Liu H, Jayakumar S, Traboulssi M, et al. Cirrhotic cardiomyopathy: implications for liver transplantation. Liver Transpl 2017;23:826–35.
[13] Murata M, Iwabana T, Yamura Y, et al. A real-time three-dimensional echocardiographic quantitative analysis of left atrial function in left ventricular diastolic dysfunction. Am J Cardiol 2008;102:1097–102.
[14] Wang W, Thompson DR, Chair SY, et al. A psychometric evaluation of a Chinese version of the Cardiac Depression Scale. J Psychosom Res 2008;65:123–9.
[15] ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:1117–34.
[16] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212–9.
[17] Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(10 Suppl 3):S158–168.
[18] Moadel A, Zamirian M, Yazdani M, et al. The correlation between echocardiographic findings and QT interval in cirrhotic patients. Int Cardiovasc Res J 2014;8:39–43.
[19] Li L, Liu HR, Shi JL, et al. Clinical investigation of Q-T prolongation in hepatic cirrhosis. Zhonghua Yi Xue Za Zhi 2007;87:2717–8.
[20] Bernardi M, Calandra S, Colantonio A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28–34.
[21] Bernal V, Pascual I, Lanas A, et al. Cardiac function and aminoterminal pro-brain natriuretic peptide levels in liver-transplanted cirrhotic patients. Clin Transplant 2012;26:111–6.
[22] Torregrosa M, Aguaire S, Dos I, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68–74.
[23] Genovesi S, Prata Pizzala DM, Pozzi M, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) 2009;116:851–9.

Formal analysis: Zhi-Ping Qian.
Project administration: Zheng-Guo Zhang.
Resources: Yu-Yi Zhang.
Software: Ying Zou.
Supervision: Hong-Zhou Lu.
Visualization: Jie-Fei Wang.
Writing – original draft: Wei Yuan.
Writing – review and editing: Hong-Ying Guo.
Hong-ying Guo orcid: 0000-0002-9282-9638.
[24] Inserre J, Perello A, Agullo L, et al. Left ventricular hypertrophy in rats with biliary cirrhosis. Hepatology 2003;38:589–98.
[25] Papastergiou V, Skorda L, Lisgos P, et al. Ultrasonographic prevalence and factors predicting left ventricular diastolic dysfunction in patients with liver cirrhosis: is there a correlation between the grade of diastolic dysfunction and the grade of liver disease? Sci World J 2012;2012:615057–62.
[26] Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511–7.
[27] VanWagner LB, Umtal S, Lapin B, et al. Use of six-minute walk test to measure functional capacity after liver transplantation. Phys Ther 2016;96:1456–67.
[28] Ribeiro HS, Mauricio SF, Antonio da Silva T, et al. Combined nutritional assessment methods to predict clinical outcomes in patients on the waiting list for liver transplantation. Nutrition 2018;47:21–6.
[29] de Lima DC, Ribeiro HS, Cristina R, et al. Functional status and heart rate variability in end-stage liver disease patients: association with nutritional status. Nutrition 2015;31:971–4.
[30] Blumenthal JA, Babjak MA, O’Connor C, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA 2012;308:465–74.
[31] Lainscak M, Blue L, Clark AL, et al. Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13:115–26.
[32] Besheer T, El-Bendary M, Elalfy H, et al. Prediction of fibrosis progression rate in patients with chronic hepatitis C genotype 4: Role of cirrhosis risk score and host factors. J Interferon Cytokine Res 2017;37:97–102.
[33] Razek A, Khashaba M, Abdalla A, et al. Apparent diffusion coefficient value of hepatic fibrosis and inflammation in children with chronic hepatitis. Radiol Med 2014;119:903–9.